Business Description
Generate Biomedicines Inc
NAICS : 541714
SIC : 2834
ISIN : US3709201004
Description
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.23 | |||||
Equity-to-Asset | -1.87 | |||||
Debt-to-Equity | -0.11 | |||||
Debt-to-EBITDA | -0.33 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 5.81 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 51.62 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74.54 | |||||
9-Day RSI | 66.43 | |||||
14-Day RSI | 60.66 | |||||
3-1 Month Momentum % | -8.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.85 | |||||
Quick Ratio | 2.85 | |||||
Cash Ratio | 2.69 | |||||
Days Sales Outstanding | 3.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -737.04 | |||||
Net Margin % | -636.99 | |||||
EBITDA Margin % | -653.71 | |||||
FCF Margin % | -640.06 | |||||
OCF Margin % | -629.04 | |||||
ROA % | -47.89 | |||||
ROIC % | -140.7 | |||||
ROC (Joel Greenblatt) % | -233.24 | |||||
ROCE % | -65.23 | |||||
Moat Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 50.14 | |||||
EV-to-EBIT | -7.24 | |||||
EV-to-Forward-EBIT | -4.85 | |||||
EV-to-EBITDA | -7.7 | |||||
EV-to-Revenue | 50.34 | |||||
EV-to-Forward-Revenue | 56.46 | |||||
EV-to-FCF | -7.86 | |||||
Earnings Yield (Greenblatt) % | -13.81 | |||||
FCF Yield % | -10.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GENB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Generate Biomedicines Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 31.893 | ||
| EPS (TTM) ($) | -2.18 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 60.66 | ||
| 14-Day ATR ($) | 0.909496 | ||
| 20-Day SMA ($) | 14.15275 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 11 - 18.18 | ||
| Shares Outstanding (Mil) | 128.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Generate Biomedicines Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Generate Biomedicines Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 107 days | ||
| General meeting for 2026 | 2026-08-06 | 14.49 (+1.54%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 14.49 (+1.54%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 15:20 | 12.87 (-12.27%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 15.30 (-0.78%) |
Show
Entries
Generate Biomedicines Inc Frequently Asked Questions
What is Generate Biomedicines Inc(GENB)'s stock price today?
The current price of GENB is $15.63. The 52 week high of GENB is $18.18 and 52 week low is $11.00.
When is next earnings date of Generate Biomedicines Inc(GENB)?
The next earnings date of Generate Biomedicines Inc(GENB) is 2026-11-30 Est..
Does Generate Biomedicines Inc(GENB) pay dividends? If so, how much?
Generate Biomedicines Inc(GENB) does not pay dividend.
Guru Commentaries on NAS:GENB
No articles.
Press Release
Articles on Generate Biomedicines Inc
Is Generate Biomedicines Inc (GENB) Facing Challenges After Q2 Revenue Miss? GF Score: 6/100
7 days ago
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers